Management of Symptomatic Uterine Arteriovenous Malformations After Gestational Trophoblastic Disease The Brazilian Experience and Possible Role for Depot Medroxyprogesterone Acetate and Tranexamic Acid Treatment

Nenhuma Miniatura disponível
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2018
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Editora
SCI PRINTERS & PUBL INC
Autores
BRAGA, Antonio
LIMA, Lana
PARENTE, Raphael Camara Medeiros
CELESTE, Roger Keller
REZENDE FILHO, Jorge de
AMIM JUNIOR, Joffre
SUN, Sue Yazaki
UBERTI, Elza
Citação
JOURNAL OF REPRODUCTIVE MEDICINE, v.63, n.43256, p.228-239, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVE: To identify predictive variables of heavy vaginal bleeding from uterine arteriovenous malformation (uAVM) after gestational trophoblastic disease (GTD) and review outcomes with different treatment strategies. STUDY DESIGN: This is a retrospective study of patients with uAVM presenting with vaginal bleeding after postmolar follow-up or treatment for postmolar gestational trophoblastic neoplasia, with normal hCG levels for at least 6 or 12 months, respectively, followed at 9 Brazilian GTD reference centers, from January 2004-January 2016. Patients were treated preferentially with uterine artery embolization (UAE), but when UAE was not available, depot medroxyprogesterone acetate and tranexamic acid (DMPA + TA) was offered. RESULTS: The incidence of symptomatic uAVM after GTD was 0.6% (39/6,129). Risk factors associated with class III-IV hemorrhage included number of previous curettages (aRR 4.23, 95% CI 1.36-13.1, p=0.013), uterine artery index of resistance <= 0.32 (aRR 35.2, 95% CI 3.58-347.5, p=0.002), and uterine artery peak systolic velocity >= 78.7 cm/s (aRR 10.7, 95% CI 1.15-100.6, p=0.037). Patients with class I-II hemorrhage treated with DMPA + TA had a higher rate of uAVM resolution (N=14/16 [87.5%]) versus UAE (N=4/8 [50%], p=0.033). Patients with class III-IV hemorrhage were 87% less likely to have successful treatment with DMPA + TA compared to class I-II hemorrhage (cRR 0.13, 95% CI 0.02-0.83, p=0.013). CONCLUSION: Although UAE is preferred for cases of heavy vaginal bleeding, there may be a role for DMPA + TA in the management of less severe bleeding complications.
Palavras-chave
Brazil, depot medroxyprogesterone acetate, gestational trophoblastic disease, tranexamic acid, uterine artery embolization, uterine arteriovenous malformation
URI
https://observatorio.fm.usp.br/handle/OPI/29673
Referências
  1. [Anonymous], 2008, ADV TRAUM LIF SUPP D
  2. Bagga Rashmi, 2008, Medscape J Med, V10, P12
  3. Belfort P, 2006, REV BRAS GINECOL OBS, V28, P112, DOI 10.1590/S0100-72032006000200007
  4. Biscaro A, 2015, REV BRAS GINECOL OBS, V37, P42, DOI 10.1590/SO100-720320140005198
  5. Braga A, 2016, J REPROD MED, V61, P224
  6. Braga A, 2014, J REPROD MED, V59, P241
  7. FLEMING H, 1989, OBSTET GYNECOL, V73, P209
  8. Flynn MK, 1996, OBSTET GYNECOL, V88, P650, DOI 10.1016/0029-7844(96)00122-6
  9. Igbinedion BOE, 2016, PAKIST J RADIOL, V23, P22
  10. Ju D, 2015, TAIWAN J OBSTET GYNE, V54, P654, DOI 10.1016/j.tjog.2014.06.008
  11. Khatree MHD, 1999, AUST NZ J OBSTET GYN, V39, P378, DOI 10.1111/j.1479-828X.1999.tb03424.x
  12. Krishnaswamy P, 2014, P OBSTET GYNECOL, V4, P4
  13. Lee TY, 2014, ACTA RADIOL, V55, P1145, DOI 10.1177/0284185113514222
  14. Maesta I, 2012, REV BRAS GINECOL OBS, V34, P143, DOI 10.1590/S0100-72032012000400001
  15. McGrath S, 2012, J REPROD MED, V57, P319
  16. Morikawa M, 2006, OBSTET GYNECOL, V108, P751, DOI 10.1097/01.AOG.0000191584.28717.2c
  17. Ngan HYS, 2015, INT J GYNECOL OBSTET, V131, pS123, DOI 10.1016/j.ijgo.2015.06.008
  18. Ngan HYS, 2002, INT J GYNECOL OBSTET, V77, P285
  19. Oride A, 2014, J OBSTET GYNAECOL RE, V40, P1807, DOI 10.1111/jog.12370
  20. Peitsidis P, 2011, ARCH GYNECOL OBSTET, V284, P1137, DOI 10.1007/s00404-011-2067-7
  21. Simbar M, 2007, J FAM PLAN REPROD H, V33, P271, DOI 10.1783/147118907782101887
  22. Dantas PRS, 2017, GYNECOL ONCOL, V147, P364, DOI 10.1016/j.ygyno.2017.09.007
  23. SONG JY, 1995, HUM REPROD, V10, P797, DOI 10.1093/oxfordjournals.humrep.a136040
  24. Takeuchi K, 2003, OBSTET GYNECOL, V102, P843, DOI 10.1016/S0029-7844(03)00707-5
  25. Tasmin SF, 2014, DINAJPUR MED COL J, V7, P63
  26. Timmerman D, 2000, EUR J OBSTET GYN R B, V92, P171, DOI 10.1016/S0301-2115(00)00443-7
  27. Timor-Tritsch IE, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2015.12.024
  28. Touhami O, 2014, EUR J OBSTET GYN R B, V181, P54, DOI 10.1016/j.ejogrb.2014.07.023
  29. Vilos AG, 2015, HUM REPROD, V30, P1599, DOI 10.1093/humrep/dev097
  30. Vilos GA, 2017, INT J WOMENS HLTH WE, V3
  31. Yang JJ, 2005, INT J GYNECOL OBSTET, V89, P114, DOI 10.1016/j.ijgo.2004.11.037

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/57